- Synthesis and photoelectric properties of IrIIIcomplexes using fluorobenzylimidazole[2,1-b]thiazole derivatives as primary ligands
-
3-Methyl-6-(3,5-difluorophenyl)imidazo[2,1-b]thiazole (mdfpit) and 3-methyl-6-(3,4,5-trifluorophenyl)imidazo[2,1-b]thiazole (mtfpit) were easily prepared from thiourea, acetone, and 3,5-difluorobenzoyl bromide or 3,4,5-trifluorobenzoyl bromide. These were used as primary ligands to synthesize twelve phosphorescent IrIIIcomplexes with picolinic acid (pic), isoquinoline-3-carboxylic acid (3-IQA), quinoline-2-carboxylic acid (2-QA), 2-(pyridin-2-yl)phenol (2-ylppy), 2-(2,4-difluorophenyl)pyridine (dfppy), and pyridine-2-sulfonic acid (2-sappy) as auxiliary ligands. Their structures, photoluminescence, and electrochemical properties were investigated. Upon introducing more fluorine atoms into the benzene ring of the primary ligand, the thermal stability, photoluminescence quantum yield (PLQY), LUMO energy level, and luminous efficiency of the resulting IrIIIcomplexes are significantly improved, and the photoluminescence emission spectra are blue-shifted. Their maximum emission wavelengths are present in the range of 517-618 nm, and the luminous colors span from the green to red light region. Using the synthesized IrIIIcomplexes as emitters, LED chips based on InGaN chip excitation were developed, which showed good performances. Among all LEDs, the PLQY of the (mtfpmt)2Ir(pic) based LED is 58.4%, and the luminous efficiency is as high as 17.11 lm W?1; the luminous efficiency of the (mdfpmt)2Ir(2-QA) based LED is 3.41 lm W?1with CIE coordinates of 0.60 and 0.38, which are very similar to the saturated standard red light emission. The results demonstrate the potential of the studied IrIIIcomplexes as candidates for LED materials.
- Liu, Xiao-Qing,Rong, Mei-Zhu,Si, Peng-Bin,Teng, Ming-Yu,Wang, Qin,Wang, Yu-Fei,Wang, Zheng-Liang,Zhang, Jie,Zhe, Hai-Feng,Zhou, Ai-Hui
-
p. 18796 - 18804
(2021/10/26)
-
- An umpolung oxa-[2,3] sigmatropic rearrangement employing arynes for the synthesis of functionalized enol ethers
-
An oxa-[2,3] sigmatropic rearrangement involving arynes is reported featuring the umpolung of ketones, where the C=O bond polarity is reversed. The in situ-generated sulfur ylides from β-keto thioethers and arynes undergo efficient rearrangement allowing the facile and robust synthesis of functionalized enol ethers in high yields and excellent functional group compatibility. Preliminary mechanistic studies rule out the possibility of Pummerer-type rearrangement operating in this case.
- Gaykar, Rahul N.,George, Malini,Guin, Avishek,Bhattacharjee, Subrata,Biju, Akkattu T.
-
supporting information
p. 3447 - 3452
(2021/05/04)
-
- SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES
-
The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
- -
-
Page/Page column 14-15; 18; 54
(2019/11/12)
-
- HETEROCYCLIC AZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES
-
The invention relates to heterocyclic compounds of formula (I) and (IV) or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
- -
-
Paragraph 00302
(2018/06/30)
-
- OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF
-
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.
- -
-
Paragraph 0500; 0501; 0502
(2016/12/26)
-
- Practical asymmetric synthesis of a chiral piperazinone derivative
-
A practical asymmetric route to a chiral piperazinone derivative, a fragment of MK-3207, is reported. The amine-bearing benzylic stereocenter is introduced via an asymmetric Pd-catalyzed hydrogenation of a cyclic sulfimidate in the presence of a chiral phosphine ligand. An efficient synthesis of the hydrogenation substrate is described, together with process development of the hydrogenation step and elaboration of the resulting cyclic sulfamate product to the desired piperazinone.
- McLaughlin, Mark,Belyk, Kevin,Chen, Cheng-Yi,Linghu, Xin,Pan, Jun,Qian, Gang,Reamer, Robert A.,Xu, Yingju
-
p. 1052 - 1060
(2013/09/12)
-
- PROCESS FOR MAKING CGRP RECEPTOR ANTAGONIST
-
The invention encompasses a novel process for making 2-[(8R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide, which is a CGRP receptor antagonist useful for the treatment of migraine, using an asymmetric phase-transfer catalysis route. The invention also encompasses an efficient and practical synthesis of the (R)-acid intermediate, and generates the benzylic stereocenter in an enantioselective manner.
- -
-
Page/Page column 64-65
(2011/02/24)
-
- PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
-
The present invention relates to the identification of inventive pyrimidine-2,4,6- triones (PYT compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the inventive PYT compounds.
- -
-
Page/Page column 109
(2010/11/18)
-
- Spiro Compounds As NPY Y5 Receptor Antagonists
-
The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;Z1 is H, C1-C4 alkyl or F;Z is CH2, CH(C1-C4 alkyl), C(C1-C4 alkyl)2 or a bond;A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or —C(═O)—X; or —O(CH2)0-1R1;B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom;R1 is —(C1-C4)alkyl(C1-C4)alkoxy; or C3-C8 cycloalkyl; or R1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or R1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;X is OR2 or NR3R4;R2 is C1-C4 alkyl;R3 is hydrogen or together with R4 and the nitrogen form a 5-6 saturated membered ring;R4 is C3-C8 cycloalkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.
- -
-
Page/Page column 46
(2009/08/18)
-
- INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH
-
Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5'-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP- galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria.
- -
-
Page/Page column 50-51
(2009/12/05)
-
- Inhibitors of UDP-galactopyranose mutase thwart mycobacterial growth
-
Galactofuranose (Galf) residues are fundamental components of the cell wall of mycobacteria. A key enzyme, UDP-galactopyranose mutase (UGM), that participates in Galf incorporation mediates isomerization of UDP-Galf from UDP-galactopyranose (UDP-Galp). UGM is of special interest as a therapeutic target because the gene encoding it is essential for mycobacterial viability and there is no comparable enzyme in humans. We used structure-activity relationships and molecular design to devise UGM inhibitors. From a focused library of synthetic aminothiazoles, several compounds that block the UGM from Klebsiella pneumoniae or Mycobacterium tuberculosis were identified. These inhibitors block the growth of M. smegmatis. Copyright
- Dykhuizen, Emily C.,May, John F.,Tongpenyai, Aimon,Kiessling, Laura L.
-
p. 6706 - 6707
(2008/12/22)
-
- 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
-
The present invention relates to a method of treating disorders by administering a compound of the formulae IA-IF. These compounds are tetrahydroisoquinolines of the following structure: wherein R1-R8 for compounds of each of the formulae IA, IB, IC, ID, IE and IF are as described herein.
- -
-
Page/Page column 25
(2010/11/08)
-
- ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS
-
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
- -
-
Page/Page column 91-92
(2010/02/11)
-
- Diaminothiazoles having antiproliferative activity
-
Disclosed are novel diaminothiazoles that are selective inhibitors of Cdk4. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds as well as intermediates useful in the preparation of the compounds.
- -
-
-
- Antifungal amine derivatives and processing for producing the same
-
Novel amine derivatives having an excellent antimycotic effect represented by general formula (1) below and salts thereof are provided. [in the formula (1, R1represents a C1-5alkyl group which may be halogenated, R2represents 4-(1,1-dimethylalkyl)benzyl group, 4-(1-methyl-phenylethyl)benzyl group, 1-or 2-naphthylmethyl group, or a hydrocarbon group having 3,3-dimethyl-1-butynyl group or a phenyl group at its terminal and 1 to 3 double bonds; R3represents oxygen atom or a methylene group which may be substituted by a C1-4alkyl group; and R4represents 1-or 2 naphthyl group or a phenyl group which may be substituted.
- -
-
-
- Process for producing optically active carbinols
-
The present invention relates to a process for producing optically active halomethyl phenyl carbinols of the formula (1), comprising reducing halomethyl phenyl ketones of the formula (2) using an asymmetric reducing agent obtained from boranes and optically active α-phenyl-substituted-β-amino alcohols of the formula (3) or optically active α-non-substituted-β-amino alcohols of the formula (4). The present invention further relates to a process for producing optically active carbinols, comprising reacting a prochiral keytone with an asymmetric reducing agent obtained from optically active β-amino alcohols of the formula (5), a metal boron hydride and Lewis acid or lower dialkyl sulfuric acid. All of the formulas (1) to (5) are the same as shown in the specification.
- -
-
-